ISPOR - Health Care Costs Associated With First- And Second-Line Switching Of Biologic Disease-Modifying Antirheumatic Drugs

Full Text

Health Care Costs Associated With First- And Second-Line Switching Of Biologic Disease-Modifying Antirheumatic Drugs

Abstract

Authors

L. Rosenblatt F. Lobo M. You T. Hebden

Back to Volume 16, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now